Revolution Medicines, Inc. (RVMD)

Market Cap	6.86B
Revenue (ttm)	n/a
Net Income (ttm)	-697.51M
Shares Out	186.27M
EPS (ttm)	-4.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	57,151
Open	36.81
Previous Close	36.63
Day's Range	36.81 - 36.81
52-Week Range	29.17 - 62.40
Beta	1.06
Analysts	Strong Buy
Price Target	69.50 (+88.81%)
Earnings Date	Aug 11, 2025

About TGI

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 13, 2020
• Employees: 534
• Stock Exchange: NASDAQ
• Ticker Symbol: RVMD
• Website: https://www.revmed.com

Analyst Summary

According to 12 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price target is $69.5, which is an increase of 88.81% from the latest price.

Price Target

$69.5

(88.81% upside)

Analyst Consensus: Strong Buy